Earlier this year, the CFDA introduced significant changes to the drug and device approval process.
China’s medtech influence is beginning to threaten the West’s dominance.
As the continent becomes a bigger player, western companies should explore the potential prospects.
Denying the agency to inspect your facility is a violation.
Get to know the local government, including the available benefits and incentives first.
The country can’t ignore the fact that Asia is the future of medtech growth.
Don’t skimp on conducting due diligence.
How are you protecting your IP and keeping talent from going overseas?
Companies must be aware of the changing clinical trial regulatory environment for devices in China.
With the largest patient population in the world, the region has high growth potential over the next few years.